TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07189871: 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Sponsor: Radiopharm Theranostics, Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 61 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,809,190

Rescue Site Savings

+$2,513,280

Unlock Full NCT07189871 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07189871 Rescue Dossier →